Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

• Status: Active, not recruiting
• Trial end date: 2022-12-31

Summary

This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as eotuzumab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide, dexamethasone, and eotuzumab with cyclophosphamide may work better in treating patients with primary amyloidosis.

• Phase: Phase 2

Details

• Lead Sponsor: Barbara Ann Karmanos Cancer Institute
• Collaborators: Bristol-Myers Squibb; Multiple Myeloma Research Consortium; National Cancer Institute (NCI)
• Treatments: BB 1101; Cyclophosphamide; Dexamethasone; Dexamethasone acetate; Elotuzumab; Ichthammol; Lenalidomide; Thalidomide